Endologix Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/16/2020)
| Balance Sheet | Total Assets | 307,164,000.00 | ROE | – |
| Balance Sheet | Total Equity | 63,856,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -455,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -30,025,000.00 | – | – |
| Cashflow | Operating Cash Flow | -29,570,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -3.84 | Div. Yield | – |
| Income | Net Income | -64,757,000.00 | P/E | – |
| Income | Shares Outstanding | 16,863,800.00 | P/B | – |
| Income | Total Revenue | 143,370,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Endologix, Inc. (Endologix) is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company´s principal product is a stent graft and delivery system (ELG System), for the treatment of abdominal aortic aneurysms (AAA) through endovascular repair (EVAR). Its ELG System consists of a self-expanding cobalt chromium alloy stent covered by expanded polytetrafluoroethylene (ePTFE) graft material (ELG Device) and an accompanying delivery catheter. Once its ELG Device is fixed in its proper position within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. Its ELG System consists of the Company´s ELG Device and catheter delivery system. It also offers proximal aortic extensions and limb extensions, which attach to the main body of its ELG Device.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.endologix.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more